With 2.73 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.79 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $13.145 whereas the lowest price it dropped to was $12.46. The 52-week range on NEOG shows that it touched its highest point at $19.88 and its lowest point at $11.46 during that stretch. It currently has a 1-year price target of $16.17. Beta for the stock currently stands at 1.23.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NEOG was up-trending over the past week, with a rise of 7.66%, but this was up by 1.95% over a month. Three-month performance dropped to -11.03% while six-month performance fell -13.84%. The stock lost -34.12% in the past year, while it has gained 7.66% so far this year. A look at the trailing 12-month EPS for NEOG yields -0.11 with Next year EPS estimates of 0.08. For the next quarter, that number is -0.01. This implies an EPS growth rate of 31.25% for this year and 400.00% for next year.
Float and Shares Shorts:
At present, 216.70 million NEOG shares are outstanding with a float of 216.15 million shares on hand for trading. On 2024-12-13, short shares totaled 21.17 million, which was 977.0001000000001 higher than short shares on 1731628800. In addition to Mr. John Edward Adent as the firm’s President, CEO & Director, Mr. David H. Naemura serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 1.1884999 of NEOG’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-08-31, NEOG reported revenue of $216964000.0 and operating income of $2257000.0. The EBITDA in the recently reported quarter was $32806000.0 and diluted EPS was -$0.06.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NEOG since 2 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With NEOG analysts setting a high price target of 16.5 and a low target of 15.0, the average target price over the next 12 months is 15.75. Based on these targets, NEOG could surge 26.24% to reach the target high and rise by 14.77% to reach the target low. Reaching the average price target will result in a growth of 20.5% from current levels.
Analysts have provided yearly estimates in a range of -$0.02656985 being high and -$0.02679531 being low. For NEOG, this leads to a yearly average estimate of -$0.026667.
